Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

4 months ago 17
Suniway Group of Companies Inc.

Upgrade to High-Speed Internet for only ₱1499/month!

Enjoy up to 100 Mbps fiber broadband, perfect for browsing, streaming, and gaming.

Visit Suniway.ph to learn

Scroll Up

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.

Individuals can access the conference call by dialing:

US domestic callers: (888) 346-3970

Outside US callers: (412) 902-4297

Get the latest news
delivered to your inbox

Sign up for The Manila Times newsletters

By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.

Patent and License Information: standardbio.com/legal/notices.

©2025 Standard BioTools Inc. All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:

David Holmes

[email protected]

This website uses cookies. By continuing to browse the website, you are agreeing to our use of cookies. Read More.

Read Entire Article